Free Papers

Presbyopia treatment with eye-drops: an eight-year retrospective study

Free Paper Details

First Author: G.Benozzi ARGENTINA

Co Author(s):    G. Benozzi   C. Perez   J. Leiro   S. Facal   B. Orman        

Abstract Details

Purpose:

To assess the safety and efficacy through time, of patients pharmacologically treated with Benozzi’s method for presbyopia.

Setting:

These is a non-surgical option for emmetropic presbyopic patients who do not wish to wear glasses, which is a pharmacological treatment with eye drops.

Methods:

A non-randomized case-series retrospective study was settled, including emmetropic patients with binocular uncorrected distance visual acuity (UDVA) of 25/20 or better, and with uncorrected near visual acuity (UNVA) at least Jaeger 2 or worse. The study was realise from January 2011 to June 2018, with at least 1-year follow-up, in Argentina, Buenos Aires. Patients were treated with a combination of pilocarpine and diclofenac preservative-free eye drops (Benozzi Method; US 8.524.758 B2- EP1.938.839 B1). The principal result evaluated was binocular UNVA at different follow-up times. Other considerations, as the UDVA and presence of side effects were assessed.

Results:

917 patients were included with a mean age at baseline of 48.66±3.74 years old (40 to 59). The baseline mean UNVA was 0.29±0.13 logMAR and after 8 years of follow-up was 0.02±0.04 logMAR. The binocular UDVA at baseline was 0.00±0.01logMAR and after 8 years of follow-up was 0.03±0.04 logMAR. The patients who remained under the treatment spontaneously resolved all side effects described (decrease of light perception, headaches, symptoms of ocular surface dryness and dizziness).

Conclusions:

This study shows the efficacy and safety of the pharmacological treatment of presbyopia. This treatment improved the UNVA without affecting the UDVA. All described side effects were well tolerated and resolute during the first year of treatment.

Financial Disclosure:

... has significant investment interest in a company producing, developing or supplying product or procedure presented, ... has significant investment interest in a competing company